Internal medicine

Pathology

Pediatrics

Clinical endpoint

Virus

Placebo

Cytomegalovirus

Valaciclovir

Biology

Obstetrics

Surgery

Randomized controlled trial

Herpesviridae

Immunology

Alternative medicine

Viral disease

Pregnancy

Genetics

Medicine

The Lancet

Valaciclovir is effective in reducing the rate of fetal cytomegalovirus infection after maternal primary infection acquired early in pregnancy. Early treatment of pregnant women with primary infection might prevent termination of pregnancies or delivery of infants with congenital cytomegalovirus.

Valaciclovir to prevent vertical transmission of cytomegalovirus after maternal primary infection during pregnancy: a randomised, double-blind, placebo-controlled trial